[Serum glycosaminoglycans in Graves' disease patients]. 2006

Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
Katedry i Zakładu Chemii Klinicznej i Diagnostyki Laboratoryjnej w Sosnowcu oraz Slaskiej Akademii Medycznej w Katowicach. winsz@slam.katowice.pl

The aim of the study was to determine the blood serum sulfated glycosaminoglycans (GAGs) and hyaluronic acid (HA) concentration of Graves' disease patients before treatment and after attainment of the euthyroid state. The study was carried out on the blood serum obtained from 17 patients with newly recognised Graves' disease and from the same patients after attainment of the euthyroid state. Graves' patients had not any clinical symptoms neither of ophthalmopathy nor pretibial myxedema. GAGs were isolated from the blood serum by the multistage extraction and purification using papaine hydrolysis, alkali elimination, as well as cetylpyridium chloride binding. Total amount of GAGs was quantified by the hexuronic acids assay. HA content in obtained GAGs sample was evaluated by the ELISA method. Increased serum concentration of sulfated GAGs in non-treated Graves' disease patients was found. Similarly, serum HA level in untreated patients was significantly elevated. The attainment of euthyroid state was accompanied by the decreased serum sulfated GAGs level and by normalization of serum HA concentration. In conclusion, the results obtained demonstrate that the alterations of GAGs metabolism connected with Graves' disease can lead to systemic changes of the extracellular matrix properties.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006025 Glycosaminoglycans Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine (see ACETYLGLUCOSAMINE) or N-acetylgalactosamine (see ACETYLGALACTOSAMINE). Glycosaminoglycan,Mucopolysaccharides
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
September 1996, Acta dermato-venereologica,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
July 1990, Clinical endocrinology,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
February 1993, Nihon Naibunpi Gakkai zasshi,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
April 1999, Thyroid : official journal of the American Thyroid Association,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
January 1993, Experimental and clinical endocrinology,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
November 1992, Clinical chemistry,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
June 1995, European journal of clinical investigation,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
April 2013, Endocrine regulations,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
July 2000, Saudi medical journal,
Katarzyna B Winsz-Szczotka, and Krystyna Z Olczyk, and Ewa M Koźma, and Katarzyna B Komosińska-Vassev, and Grzegorz R Wisowski, and Czesław Marcisz
March 2022, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!